logo-loader
viewMedlab Clinical Ltd

Medlab Clinical progresses through trials, overseas registration process

Medlab Clinical (ASX:MDC) has completed the first stage medical trials of its NanaBis product, and is encouraged by its progress with US and European medical registration administrations.

CEO Sean Hall distinguishes Medlab Clinical (ASX:MDC) from other "pot stocks" through its focus on proven medical outcomes and its breadth of products.

Hall says the company has sizeable upside as potential applications for its product include not only pain treatments but also other chronic health issues such as Type II Diabetes and depression.

Quick facts: Medlab Clinical Ltd

Price: 0.385 AUD

ASX:MDC
Market: ASX
Market Cap: $82.92 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medlab Clinical forges ahead in new vitamin trials for chronic illnesses

Medlab Clinical Ltd (ASX:MDC) chief executive officer Sean Hall tells Proactive Investors how the company is tapping into new areas of its “therapeutic toolkit” to better assist those with chronic health conditions.   Hall says there has been a shortfall in the standard of...

on 8/5/19

2 min read